The 2017 classification of Periodontal Diseases and Conditions includes:Periodontitis:

Necrotizing periodontal diseases
Periodontitis
Periodontitis as a manifestation of systemic diseaseTherefore, in accordance to the 2017 classification, a diagnosis would be achieved through the patient assessment individually on the basis of:

Type
Distribution: localised (up to 30% of teeth) or generalised (more than 30% of teeth) and the molar/incisor pattern
Stage and grading
Stages: I (early/mild) with <15% or <2mm interproximal bone loss, II (moderate) with coronal third of root bone loss, III (severe) with mid third of root bone loss, IV (very severe) with apical third of root bone loss
Grading: A (slow) with <0.5% bone loss/age, B (moderate) with 0.5-1.0% bone loss/age, C (rapid) with >1.0% bone loss/age
Status: stable, remission or unstable (see Table 1)
Risk factors, which include systemic diseases such as diabetes or extrinsic factors such as smoking. Treatment
There is professional agreement among dentists that smoking cessation and good oral hygiene are key to effective treatment and positive outcomes for patients. Similarly, any plaque retentive factors which exist and are modifiable should be corrected, such as overhangs on restorations. Treatment can involve both non-surgical and surgical therapies. The typical initial treatment known to be effective is scaling and root planing (SRP) to mechanically debride the depths of the periodontal pocket and disrupt the biofilm present. This is done using a powered ultrasonic or sonic scaler and/or unpowered hand instruments. "In patients with chronic periodontitis, subgingival debridement (in conjunction with supragingival plaque control) is an effective treatment in reducing probing pocket depth and improving the clinical attachment level.
It is unclear if it is more or less effective than other agents such as droperidol, metoclopramide, or ondansetron. Gastroparesis
The granisetron patch (Sancuso) has been studied for use in gastroparesis, though it is not FDA approved for this indication. Other
Is a possible therapy for nausea and vomiting due to acute or chronic medical illness or acute gastroenteritis
Treatment of cyclic vomiting syndrome although there are no formal trials to confirm efficacy. Adverse effects
Granisetron is a well-tolerated drug with few side effects. Headache, dizziness, and constipation are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the livers cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system. Extended release
An extended release injectable version of granisetron, known as Sustol is also available in the United States as of 2016. The long acting form is used for the treatment of both acute and delayed CINV in moderately emetogenic chemotherapy and anthrocycline and/or cyclophosphamide (AC) highly emetogenic regimens. In its review, the FDA did not grant the broad HEC label to the drug citing the focus on AC regimens, primarily breast-cancer, and lack of data. References


== Further reading ==